Insider Selling: Pacira Pharmaceuticals Director Sells 150,000 Shares of Stock (PCRX)
Pacira Pharmaceuticals (NASDAQ:PCRX) Director Andreas Wicki sold 150,000 shares of the stock on the open market in a transaction dated Monday, August 11th. The stock was sold at an average price of $101.25, for a total value of $15,187,500.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Shares of Pacira Pharmaceuticals (NASDAQ:PCRX) traded up 1.18% on Tuesday, hitting $102.12. The stock had a trading volume of 292,388 shares. Pacira Pharmaceuticals has a one year low of $35.53 and a one year high of $102.29. The stock has a 50-day moving average of $89.8 and a 200-day moving average of $76.95. The company’s market cap is $3.665 billion.
Pacira Pharmaceuticals (NASDAQ:PCRX) last released its earnings data on Thursday, July 31st. The company reported $0.04 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.25. The company had revenue of $47.20 million for the quarter, compared to the consensus estimate of $42.20 million. The company’s revenue for the quarter was up 175.2% on a year-over-year basis. On average, analysts predict that Pacira Pharmaceuticals will post $-0.25 earnings per share for the current fiscal year.
A number of research firms have recently commented on PCRX. Analysts at Wedbush raised their price target on shares of Pacira Pharmaceuticals from $98.00 to $110.00 in a research note on Friday, August 1st. Separately, analysts at Canaccord Genuity raised their price target on shares of Pacira Pharmaceuticals to $114.00 in a research note on Friday, August 1st. Finally, analysts at Jefferies Group reiterated a “buy” rating on shares of Pacira Pharmaceuticals in a research note on Friday, August 1st. They now have a $109.00 price target on the stock, up previously from $86.00. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Pacira Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $104.68.
Pacira Pharmaceuticals, Inc is a United States-based pharmaceutical company. The Company develops non-opioid products for postsurgical pain control.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.